CIBR vs IBB
First Trust NASDAQ Cybersecurity ETF vs iShares Biotechnology ETF
- • IBB has the lower expense ratio at 0.44% vs 0.58% for CIBR.
- • CIBR pays a higher dividend yield (0.39%).
Side-by-side metrics
| Metric | CIBR | IBB |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.58% | 0.44% |
Dividend yield Trailing 12-month yield. | 0.39% | 0.16% |
AUM Assets under management — bigger funds are typically more liquid. | $17.53B | $11.50B |
YTD return | 32.86% | 30.22% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 1.03 | 0.60 |
P/E ratio | 27.94 | 25.48 |
Last price | $97.59 | $217.75 |
Inception | — | — |
Issuer | First Trust | iShares |
CIBR top holdings
| CRWD | CrowdStrike Holdings Inc Class A | 8.61% |
| PANW | Palo Alto Networks Inc | 7.58% |
| CSCO | Cisco Systems Inc | 7.48% |
| AVGO | Broadcom Inc | 7.09% |
| FTNT | Fortinet Inc | 6.20% |
| OKTA | Okta Inc Class A | 4.60% |
| ZS | Zscaler Inc | 4.38% |
| NET | Cloudflare Inc | 3.87% |
| RBRK | Rubrik Inc Class A Shares | 3.07% |
| FFIV | F5 Inc | 2.89% |
IBB top holdings
| GILD | Gilead Sciences Inc | 8.94% |
| AMGN | Amgen Inc | 8.31% |
| VRTX | Vertex Pharmaceuticals Inc | 7.87% |
| REGN | Regeneron Pharmaceuticals Inc | 6.24% |
| MRNA | Moderna Inc | 5.49% |
| NTRA | Natera Inc | 3.78% |
| ARGX | argenx SE ADR | 3.36% |
| BIIB | Biogen Inc | 2.52% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 2.50% |
| ILMN | Illumina Inc | 2.41% |
About CIBR
CIBR (First Trust NASDAQ Cybersecurity ETF) is Cybersecurity companies providing network security. Managed by First Trust, the fund carries $17.5B in assets under management, an expense ratio of 0.58%, a dividend yield of 0.39%. Its largest holding is CrowdStrike Holdings Inc Class A (CRWD), which represents 8.6% of the portfolio. Technology is the fund's largest sector exposure at 95.0%.
About IBB
IBB (iShares Biotechnology ETF) is NASDAQ biotech and pharmaceutical companies. Managed by iShares, the fund carries $11.5B in assets under management, an expense ratio of 0.44%, a dividend yield of 0.16%. Its largest holding is Gilead Sciences Inc (GILD), which represents 8.9% of the portfolio. Healthcare is the fund's largest sector exposure at 100.0%.